Mounjaro Dosage Chart 2026: Approved Schedule, KwikPen Strengths, and Zepbound Differences
The complete Mounjaro and Zepbound (tirzepatide) dosage schedule: six dose strengths, the four-week escalation ladder, KwikPen delivery, and the difference between the diabetes and weight-loss brands.
The Approved Titration Schedule
Tirzepatide is dosed once weekly by subcutaneous injection across six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The titration ladder is four weeks per step: 2.5 mg for weeks 1-4, then 5 mg, with escalation to 7.5, 10, 12.5, or 15 mg as glycemic or weight-management targets require. The 2.5 mg dose is a start dose, not a maintenance dose — the approved maintenance range is 5-15 mg. Mounjaro is the diabetes brand (glycemic control) and Zepbound is the weight-management brand of the same molecule; the dose schedules overlap but the approved max is 15 mg weekly in both. Our tirzepatide calculator encodes the full ladder.
KwikPen and Delivery Math
Mounjaro and Zepbound ship as KwikPen single-patient pens delivering four weekly doses each, in the six strengths. The vial format exists for use with the grey-market research context and for pharmacy compounding rules when they applied — the "munjaro doses" search cluster often reflects the dose-confirmation question for those formats, and our unit converter handles the mg-to-units math. The KwikPen delivery note that matters most: pens are not strength-interchangeable mid-titration without prescriber guidance, because the whole schedule is built on four-week adaptation steps. Missed-dose rules mirror the class standard: within 96 hours (4 days), take it; beyond that, skip and resume on schedule — tirzepatide's ~5-day half-life makes it the most forgiving of the weekly molecules.
Dose-Response: What the Trial Numbers Say
The tirzepatide dose-response curve in the SURMOUNT trial series is the cleanest in the class: mean weight loss climbed with dose, from ~15% at 5 mg to ~20-21% at 10-15 mg over 72 weeks, with Zepbound's label carrying the 15 mg top dose for maximal responders. Surpass (diabetes) trials show the same escalation pattern for HbA1c. That dose-response is why the titration ladder exists: the higher doses deliver more efficacy and more GI-side-effect burden, and the four-week steps balance the two. Our semaglutide-vs-tirzepatide guide compares the ladders side by side, including the practical difference between a 2.4 mg weekly molecule (semaglutide) and a 15 mg weekly one (tirzepatide).
Mounjaro vs Zepbound vs What Comes Next
The brand split is the most common confusion point: Mounjaro = tirzepatide for type 2 diabetes, Zepbound = tirzepatide for weight management (including the KwikPen format that dominates dispensing), same molecule and dose ladder. Zepbound lawsuits over claimed side effects (gastroparesis reports) are active in 2026 — our news section tracks the litigation as it develops, and it reinforces why titration steps and prescriber oversight matter. Beyond tirzepatide, retatrutide's trial results (up to 31%) define the next rung of the ladder, and oral orforglipron defines the convenience tier. For protocol math across all of them, the calculators encode each approved and investigational ladder.
📊 Dosage Calculator & Protocol Chart
Use our free Mounjaro dosage calculator to plan your protocol:
👉 Mounjaro Dosage Calculator — Calculate exact dosing, reconstitution ratios, and injection volumes.
👉 Full Dosing Guide & Protocol Chart — Complete protocol with weekly titration schedule, side effect management, and cycle recommendations.
Important Disclaimer
This article is for educational and research purposes only. Peptides discussed may not be FDA-approved for all uses described. Always consult with a qualified healthcare provider before starting any peptide protocol. The information provided here is synthesized from published research, clinical trial data, and community discussions.
Keywords: mounjaro dosage chart, munjaro doses, mounjaro max dose, tirzepatide dosage chart, zepbound dosage chart, manjaro dosing
Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content